Furthermore, tumors formed by YAP5SA-activated melanoma cells in immunodeficient NSG mice grew despite Vemurafenib treatment, confirming YAP1-induced resistance to Vemurafenib in vivo (Fig. 1d). Here, YAP1 is linked to melanoma.